ClinicalTrials.gg
RecruitingNCT06999161BETALACT-ARCUpdated May 31, 2025

Therapeutic Drug Monitoring of Beta-lactams and Renal Hyperclearance in Patients Admitted to Intensive Care for Acute Brain Injury

An observational study in Critical Illness and Brain Injuries, sponsored by Centre Hospitalier Universitaire de Nīmes. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-31.

Primary conditionBrain InjuriesRegistry: Critical IllnessReclassifiedWhy we changed it
Registry
Critical Illness — the first condition term the registry derived for this study.
ClinicalTrials.gg
Brain Injuries
Why
  1. Critical Illness is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Brain Injuries.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Centre Hospitalier Universitaire de Nīmes · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
140
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies in Brain Injuries with a site in France — 18 open to participants now, 19 under way, none of them phase 3. Brain Injuries · France.

Planned enrollment
16th of 36
140 · median 124
Started
2025
with 3 others
Observational
36 of 72
12 open now
Primary completion
2025-11
later than 5 of 18 live
Registered
63rd of 72
by date

Among the 72 studies in Brain Injuries with a site in France, this one is the 16th largest by planned enrollment of the 36 observational ones that give a count, is one of 4 that started in 2025, is one of 36 observational ones, reaches primary completion later than 5 of the 18 other live ones, and was the 63rd registered.

Brain Injuries

947 studies on the registry are indexed under Brain Injuries; 234 are open to participants now.

Browse Brain Injuries studies →

Open to participants now

18 of the 72 studies in Brain Injuries with a site in France are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 152 Brain Injuries studies recruiting now, 77 (51%) set no upper age limit and 53 (35%) stop at 75 or younger; 38 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Brain Injuries with a site in France, or all of them as a file.
02

Study summary

Augmented Renal Clearance (ARC), defined as a supraphysiological increase in renal function, is frequently observed in critically ill patients, particularly those with acute brain injury. ARC complicates the management of renally eliminated drugs, specifically beta-lactam antibiotics, by enhancing drug clearance and thereby increasing the risk of underdosing and therapeutic failure. Although pharmacological therapeutic drug monitoring (TDM) is recommended to optimize dosing, it remains limited by issues of accessibility, highlighting the need for alternative approaches to identify at-risk patients and adjust dosing based on renal function.

Early identification of patients at risk for subtherapeutic beta-lactam plasma concentrations could enable timely dose adjustments. A combined assessment of renal function and beta-lactam TDM could enhance our understanding of the kinetics of both parameters. These data may support the development of predictive models capable of proposing individualized dosing regimens based on renal function.

Optimizing beta-lactam plasma concentrations in this patient population could improve infection management and potentially enhance clinical outcomes.

03

Conditions studied

  • Critical Illness
  • Brain Injuries

Browse trials for

Keywords

  • Beta-Lactams
  • Renal Clearance
  • Therapeutic Drug Monitoring
04

In context

Brain Injuries Reclassified

947 studies on the registry are indexed under Brain Injuries; 234 are open to participants now.

This study's planned enrollment of 140 is above the median of 100 across 302 observational studies indexed under Brain Injuries.

Browse Brain Injuries studies →

Lead sponsor

Centre Hospitalier Universitaire de Nīmes is the lead sponsor of 595 studies on the registry; 87 are open to participants now.

Compared within Brain Injuries, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The population studied included patients admitted to the intensive care unit with acute brain injury (of traumatic, vascular, infectious or immunological origin), presenting a profile of HCR and receiving antibiotic treatment with betalactam

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (≥18 years old)
  • Admitted to the intensive care unit for acute brain injury
  • Exhibiting Augmented Renal Clearance (ARC), defined by a urinary (ClCrU) greater than 130 mL/min/1.73 m² on at least one measurement
  • Receiving Therapeutic Drug Monitoring (TDM)-guided treatment with one of the following beta-lactam antibiotics: amoxicillin/clavulanic acid, cefotaxime, piperacillin/tazobactam, cefepime, or meropenem
  • Affiliated with or benefiting from a health insurance scheme

Exclusion criteria

Exclusion Criteria:

  • Estimated \<24 hours
  • Patients who have expressed opposition to study participation
  • Patients under legal protection (guardianship, curatorship, or court protection)
  • Patients currently in an exclusion period determined by participation in another study
  • Patients already enrolled in a study that precludes concurrent participation in an observational study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
140 participants (estimated)
Patient registry
No

Groups and cohorts

  • BETALACTAM Treated Patients

    Adult patients (≥18 years) admitted to intensive care for acute brain injury, presenting with an infectious episode, documented augmented renal clearance (as assessed by urinary creatinine clearance), and receiving treatment with beta-lactam antibiotics.

07

What researchers measure

Primary outcomes

  1. Plasma betalactam underdosing

    Development of a predictive model for plasma beta-lactam underdosing in critically ill patients with acute brain injury and renal hyperclearance, receiving beta-lactam therapy for an ongoing infectious episode. Plasma beta-lactam concentrations will be measured 24 hours after initiation of antibiotic therapy, and subsequently every 48 hours, or in cases of underdosing, overdosing, antibiotic switch, or significant changes in renal function.

    Time frame: 24 hours after the start of antibiotic therapy, and repeated every 48 hours or in the event of underdosing, overdosing, change of molecule or significant variation in renal function, assessed until the antibiotic therapy is stopped, for up to 14 days

Secondary outcomes

  1. Evolution of Augmented Renal Clearance

    Assessment of urinary creatinine clearance based on urine collection (8, 12, or 24-hour collection depending on center practices).

    Time frame: From date of inclusion until the date of discharge from intensive care, assessed up to 28 days

  2. Evolution of plasma Beta-lactam Concentration

    Monitoring of total plasma beta-lactam concentrations obtained through Therapeutic Drug Monitoring during the intensive care stay

    Time frame: From date of inclusion until the date of discharge from intensive care, assessed up to 28 days

  3. Relationship Between Plasma Underdosing Intensity and Level of Augmented Renal Clearance (ARC)

    Characterization of the intensity of plasma beta-lactam underdosing for each antibiotic molecule relative to the degree of ARC.

    Time frame: From date of inclusion until the date of discharge from intensive care, assessed up to 28 days

  4. Beta-lactam Dosing According to Augmented Renal Clearance Level.

    Development of a dosing nomogram for beta-lactam antibiotics tailored to the degree of ARC.

    Time frame: From date of inclusion until the date of discharge from intensive care, assessed up to 28 days

  5. Clinical outcome

    Assessment of clinical outcomes based on rates of clinical success and failure. * Clinical success is defined as the resolution of infectious symptoms present at the initiation of antibiotic therapy, allowing discontinuation of antibiotics at the end of the planned treatment duration. * Clinical failure is defined as the persistence or worsening of initial symptoms, the occurrence of superinfection (infection with newly identified pathogens), or recurrence (a new infectious episode with the same pathogen).

    Time frame: From date of inclusion until the date of discharge from intensive care, assessed up to 28 days

08

Study locations

1 of 1 sites recruiting
  • CHU de Nîmes - Hôpital Universitaire Carémeau
    Nîmes Cedex 09, 30029, France
    Recruiting
    • Claire ROGER, MD, PhD · Contact
    • Claire ROGER, MD, PhD · Principal investigator
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Nov 2025, 6 months after the start.

Of 144 non-industry observational studies under Brain Injuries, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 73. This study's planned 6 months is below that.

Counting every sponsor, half of 149 studies reached it within 31 months; a quarter within 16 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2025
First posted
May 31, 2025
StartActual
May 5, 2025
Primary completionEst.
Nov 2025
CompletionEst.
Dec 2025
Last update
May 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06999161
Responsible party
Sponsor
First posted
May 31, 2025
Start date
May 5, 2025
Primary completion
Nov 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
May 31, 2025

Study contacts

Claire ROGER, MD, pHD
Contact
claire.roger@chu-nimes.fr
+33 466683331

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion